Peaceable Tenet on Adolescent Urticaria
A fresh tenet from the European Academy of Allergy and Clinical Immunology (EAACI) recommends omalizumab as an add-on treatment for patients vulnerable 12 to 17 years with chronic spontaneous urticaria (CSU) now not sufficiently managed by antihistamines. The famous-line treatment…